BECN1 and cancer: Here we demonstrated that both sorafenib and regorafenib induced elevations in Beclin 1 and LC3-II/I in skeletal muscle, thus supporting the idea that autophagy activation may trigger muscle depletion in our experimental model, similar to previous findings in a cancer cachexia setting [44].